Trevena, Inc. · OTC:TRVN
Trevena — Q2 2020 Earnings Presentation
41 slides from Trevena's earnings presentation, Aug 10, 2020
Slide 1: Innovating for Patients
INNOVATING FOR PATIENTS Nasdaq TRVN August 2020
Slide 2: Forward-looking statements
F35:%5(-L33/-2+ S7%7)1)276 '; @41 1D@1:@ @4-@ ?@-@191:@? /;:@-5:10 5: @45? <>1?1:@-@5;: ->1 :;@ 01?/>5<@5;:? ;2 45?@;>5/-8 2-/@? >13->05:3 '>1B1:-, I:/. (@41 HC;9<-:EI ;> HC1I), @41E ->1 2;>C->0-8;;75:3 ?@-@191:@? >1281/@5:3 9-:-3191:@J? /A>>1:@ .18512? -:0 1D<1/@-@5;:?. F;>C->0-8;;75:3 ?@-@191:@? -
Slide 3: Participants / Management
5)9)2%?6 E;4)5-)2')( L)%()56,-4 )%1 C-<<51 . B:?<0:A $9.:2-.6; & C12./ E?.,<;2=. #//2,.9 '/:>> A;;71.-?8 ')$, C12./ .0*4 & &.0<4*;79@ #//2,.9 !-<6 A. D185><-/6, !.D. ')$, C12./ !.-2,*4 #//2,.9 B-<<C '459 ')$, C12./ F26*6,2*4 #//2,.9 &:.1<> (. ,:01< ')$, C12./ B<:26.:: #//2,.9 1:9 #. !:?701<, J<. Cha
Slide 4: Trevena: Innovative CNS company
5)9)2%: I2239%7-9) CNS C314%2< OLINVYK !) !$d!ca*ed !$ ad+"*) f%( * e #a$age#e$* %f ac+*e &a!$ )e,e(e e$%+g *% (e'+!(e a$ !$*(a,e$%+) %&!%!d a$a"ge)!c a$d f%( - %# a"*e($a*!,e *(ea*#e$*) a(e !$ade'+a*e. P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+""
Slide 5: Multiple Expected Catalysts
M807-40) E;4)'7)( C%7%0<676 (&)027 "7=.4 A(1 9.,.8;79 :.4.,;2=. *0762:; A?3 2020: ';<-@ 262;2*;276 %1 2021: (78426. -*;* (IC A&D' / -.9:<8-7 /7:>>593 (C#)ID-19) C-**!"-/!1)-, 3)1( I+.%/)!* C-**%'% L-,$-, I# ) (&)734 G-897;.26 :.4.,;2=. *0762:; (5<-78272-9.,.8;79) C-**!"-/!1)-, 3)1( N!1)-,!* I,01)121
Slide 6: OLINVYK commercialization
OLIN"$K> (30-')5-(-2)) -2.)'7-32: N3: A44539)( 6 P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK.c%#.
Slide 7: OLINVYK: Differentiated Profile for Acute Pain
OLIN"$K: D-**)5)27-%7)( P53*-0) *35 A'87) P%-2 (%#'/1$ :D :?5:42E65 :? 25F=ED 7@C E96 >2?286>6?E @7 24FE6 A2:? D6G6C6 6?@F89 E@ C6BF:C6 2? :?EC2G6?@FD @A:@:5 2?2=86D:4 2?5 7@C H9@> 2=E6C?2E:G6 EC62E>6?ED 2C6 :?256BF2E6 E);-7. =;-16 +4161+)4 8:)+<1+-8@=FD / )CA; ?@ 24E:G6 >6E23@=:E6D -? +0-51+)4 -6<1
Slide 8: OLINVYK: Major Unmet Need for Acute Pain
OLIN"$K: B53%( I2(-'%7-32 *35 A'87) P%-2 L(9., (*<;, 4(92,; 67769;<50;@ US ).*&$3"#,& ".",'&2)$ (/20)3", -"1+&3 4.)3 5/,4-&1 45M patients receive IV opioids annually to treat acute pain1 I) 78272-: C $590=(33,+ (5(3.,:0* ,--0*(*@ 38% 45% I) #;5:50= 7,*4 *6.:;1.;2,: C #67 :<9.,90,:: #6;(3 25,, (9;/96
Slide 9: OLINVYK: Patent Protection and Exclusivity
OLIN"$K: D-67-2'7 F531 I" M354,-2) I H<(531354,32) S+, #! #& >1,900 #& #-# ,a$* IV %')("#&! #&c$, ! a* ac+#-! c'%(a)a+') NCE .#+" 2032+ COM (a+!&+1 !:<;4591 HC0<:8:<;4:91 P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.O
Slide 10: OLINVYK: Efficacy in Phase 3 Trials
OLIN"$K: I" O4-3-( E**-'%'< %2( R%4-( O26)7 , Efficac+ achie)ed i" ha%d 'i&&(e & &#f' 'i&&(e !#de & $7.< %1;;=-($" D-24) H):, %1;;=-($" D-48) , Ra$id #"&e': $e%ce$'ib e $ai" %e ief *i'hi" 2-5 !i"('e& ,FA6C:@C A2:? C6=:67 GD. A=2463@ (A<0.01) ,FA6C:@C A2:? C6=:67 GD. A=2463(A<0.02) , OLINVYK efficac+
Slide 11: OLINVYK: Differentiated Safety and Tolerability
OLIN"$K: #)00-C,%5%'7)5-=)( S%*)7< I 30)5%&-0-7< Ad. *+ d*-" * ac,$('+ * )(*, d $' 05% (! OLINVYK-,* a, d )a,$ ',+ +,*a,$!$ d b/ da$%/ d(+ (P#a+ 3 )$.(,a% ,*$a%+ )((% d)1 P"2)&-21 4)2( "-6 TEAE (%) !-A?1-);95@5:3 H1-0-/41 D5FF5:1?? C;:?@5<-@5;: HE<;D5-#>A>5@A? &10-@5;: &;9:;81:/1 B-/7 <-5: H;@ 28A?4
Slide 12: Data in Real World Use: Complex Surgeries and Patients
Da$a in (Real W "ld U#e): C m!le' S%"ge"ie# & Pa$ien$# B96(+ 9(5., 6-:<9.,90,: I 4,+0*(3 796*,+<9,: C4251*< 5&8.*387 ;*6* .3(19)*) A A 32% B 65 @.*9: 46% B!I B 30 C7-579+2-2;2.:: -2*+.;.:, 7+:;9<,;2=. :4..8 *86.*, C#$D, ,19762, I ,*6,.9 8*26 C76,752;*6; 5.-2,*;276:: *6;2.5.;2,:, *6;2+27;2,: A M918.5
Slide 13: OLINVYK: Ease of Dosing and Administration
OLIN"$K: E%6) 3* D36-2+ %2( A(1-2-675%7-32 3 =0(3: ;6 (336> -69 -3,?0)3, +6:, (+1<:;4,5; ;(0369,+ ;6 7(;0,5; 5,,+: B74=; D7;16/: 1 5/ )6, 2 5/ =1)4: M#?:E:2= 1.5 >8 5@D6 M,:?8=6 5@D6D @G6C 3 >8 92G6 ?@E 366? 6G2=F2E65 "CA D7;16/: 30 5/ =1)4 M M M #?:E:2= 1.5 >8 5@D6 0.35 >8 / 0.5 >8 56>2?5 5@D6D H:E
Slide 14: Customer Engagement Strategy
Customer Engagement Strategy 14
Slide 15: Compelling Data Available at Launch
C3145),)26-9) D%7% A9%-0%&0) %7 L%82', &033 :<7769; -<;<9, *644,9*0(30A(;065 (5+ /6:70;(3 -694<3(9@ <7;(2, Hea$+" Ca)e P)ac+#+#'&e)* (HCP*) M M M '6H 496>:42= 6?E:EJ 2DE, 67764E:G6 #/ @A:@:5 A2:? C6=:67 C=:?:42= 52E2 :? 4@>A=6I A2E:6?ED / E2C86E65 DFC86C:6D H'*(#+a$ F')%,$a)/ C'%%#++ee* M )F3=:D965
Slide 16: Robust Set of Peer-Reviewed Publications
R3&867 S)7 3* P))5-R)9-):)( P8&0-'%7-326 C6479,/,5:0=, 6=,9=0,> 6-OLIN%'K +,=,3674,5; 796.9(4 "0);-1 I "0);-2 ,)<) 15 59'1.(&8.437 ;-+76,):A )6)4A;-; 7 59'1.(&8.437 P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK
Slide 17: Positive Feedback from Formulary Research
S7%/),30()561 P36-7-9) F))(&%'/ *531 F35180%5< M)27:1<A 7. ;<)3-074,-:; >1-? & 57:8016-); 413-4A <7 *-:-84)+-, *A !L &(K: L)*&+6 2. R&/+"$& )-P0"$2)$& (-=100; ,3+2)/+& 0&1/.-1&1 /&0,)22&%) 74% 7. .7:5=4):A ;<)3-074,-:; .16, !L &(KE; 8=*41;0-, ,)<) +4161+)44A 5-)616/.=4:2 I# 0243,-1) 66 I# ,:(420243,
Slide 18: Hospital Pharmacy Considerations
H364-7%0 P,%51%'< C326-()5%7-326 ".% 1&%4$& $/232 ../ ../ ../ D1..-9-6;1);-, )+<;-8)16 897.14-$8,826 05 /6:70;(3 *6:;: 7,9 7(;0,5; -69 5(<:,( I =640;05.1 $).-;@ 16 +7584-? 8);1-6;: H-),-;7-0-), 8--9-9-=1->-, +4161+)4 -=1,-6+-3 $28,000 7,9 *90;0*(3 9,:709(;69@ ,=,5; I :,8<,3(,2 ../ ../ C758-4416/ 0-)
Slide 19: Targeted Account Launch
%5+)7)( A''3827 L%82', I50;0(3 -6*<:: *6473,? 7(;0,5;: 05 3 2,@ :<9.0*(3 (9,(: >12 75*(.&18.*7 &(6477 7*88.3,7 >5,800 -475.8&17 .3 8-* #! 8550 (/20)3",2 8500 ASC2 C@>>F?:EJ %2C86 C68:@?2= DJDE6>D "@DA:E2= @FEA2E:6?E A>3F=2E@CJ DFC8:42= 46?E6CD 84 20&$)",3)&2 A?6DE96D:@=@8J (CE9@A65:4 C@=@C64E2= !J?6
Slide 20: Launch Timeline: Planning for Commercial Launch
L%82', -1)0-2) P3(5505. <5+,9>(@ -69 (5 ,--0*0,5; (5+ ,--,*;0=, *644,9*0(3 3(<5*/ 1Q 2021 4Q 2020 La,&c" D,736@4,5; 6-*<:;64,9--(*05. ;,(4: A4' 7 C DEA Sc"ed,$#&! C "97,<+; )=)14)*4-16 ;9),-+0)66-4 A(()'-a$ C M(5<-(*;<905. 3 =0(3 79,:,5;(;065: P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED
Slide 21: OLINVYK Additional Strategy Areas for Growth
OLIN"$K A44539%0 S75%7)+< A003:6 *35 G53:7, 61<1)4 +7:-.7+=; (9!) M M M 8C@25 :?5:42E:@? & 5@D:?8 / 25>:? #/ @A:@:5 677:424J & 72DE @?D6E C@>A=6I A2E:6?ED: 6=56C=J, @36D6, C6?2= DFC8:42= AC@465FC6D ")<1-6< & ":7+-,=:-#1;3 P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f
Slide 22: TRV027 targeting AT1 receptor in COVID-19
TRV027 NCE 'a%ge'i"g 'he AT1 %ece$'#% i" COVID-19 22
Slide 23: Modulation of ACE2 Pathway in COVID-19
M807--O5+%2 D%1%+) F531 C3532%9-586 E30405(;065 6-ACE2 796;,05 3,(+: ;6 *90;0*(3 /69465(3 04)(3(5*,: C7976)=19<: *16,: ;7 )6, -41516);-: ACE21 C L-),: ;7 )++<5<4);176 7. )6/17;-6:16 II: - A+<;-4<6/ 162<9@ )6, )*6795)4 *477, +47;: - C)6 4-), ;7 A#D$ I 8<4576)9@ -5*741:5 I :;973-SARS-C. -2 C 66% - 94%
Slide 24: TRV027: Novel MOA for COVID-19
R"027: N): MOA *35 CO"ID-19 M,*/(50:4 ;(9.,;,+ ;6 04796=, 3<5. -<5*;065 (5+ 79,=,5; ()5694(3 *36;;05. %#&027 A6027;.6:26 II A(1 9.,.8;79 C.44 :<9/*,. C.44 26;.9279 G 8:7<-16 F-)::-;<16 %#&027 1; <0-764A ;-4-+<1>-A%1 :-+-8<7: )/761;< $).-<A I <74-:)*141<A -;<)*41;0-, 16 C700 8)<1-6<; 24 L93, 6*5&.6 A
Slide 25: TRV027 COVID-19 Study
R"027 CO"ID-19 S78(< - I14)5-%0 C300)+) L32(32 I5=,:;0.(;, ,--,*; 6-#!%027 65 )366+ *36;;05., 3<5. -<5*;065, (5+ 6;/,9 *3050*(3 6<;*64,: C #)6,751A-,, ,7<*4--*416,, 84)+-*7-+76;9744-, 8977.-7.-+76+-8; :;<,@ C = B60 (30 8-9 )95) C!&ID-19 8);1-6;: -"@DA:E2=:K65, ?@?-G6?E:=2E65 -N18 J62CD @=5 C I& 16.<
Slide 26: Multiple Expected Catalysts
M807-40) E;4)'7)( C%7%0<676 -78272-9.,.8;79) A?3 2020: ';<-@ 262;2*;276 A&D' / -.9:<8-7 /7:>>593 C-**!"-/!1)-, 3)1( :.4.,;2=. *0762:; (&)734 G-897;.26 :.4.,;2=. *0762:; (5<-78272-9.,.8;79) C-**!"-/!1)-, 3)1( N!1)-,!* I,01)121% -, D/2' A"20% $7C :;<-@ -*;* ("IDA) #;5:50 ?=1 05=:<01< 24%/ C"' C-**!"-/
Slide 27: TRV250: Novel MOA for Acute Treatment of Migraine
R"250: N): MOA *35 A'87) 5)%71)27 3* M-+5%-2) D,3;( 9,*,7;69: $5;(77,+ 76;,5;0(3 05 CN" :7(*, M0.9(05, 9,79,:,5;: ( 3(9., 4(92,; 67769;<50;@; ;6;(3 40.9(05, +9<. 4(92,; = B$3.5B D-4<) :-+-8<7:; 0)>-=619=-,1;<:1*=<176 <0:7=/07=< <0-*:)16 Every year in the US1: C 20-30% 7. 51/9)16-:<..-9-9: ,7 67; 9-:
Slide 28: TRV250: Preclinical and Phase 1 Data
R"250: #)00-30)5%7)( -2 P,1 H)%07,< "30827))5 PK S78(< "<)*<;(5,6<: +6:,: <7 ;6 30 4. :;<+0,+; 56 "AE: 6):,9=,+ $16/4-,7;-80):5)+7316-<1+; 7. %#&250 /1>-6 *A $C 162-+<176 C &,33 ;63,9(;,+, >0;/ 56 "AE: (*96:: )96(+ 9(5., 6-+6:,: C P9,+0*;()3, PK: +6:,-796769;065(3 ),;>,,5 0.1 4. ;6 30 4. "C C H(3--3
Slide 29: TRV734: Maintenance Therapy for Opioid Use Disorder
R"734: M%-27)2%2') ,)5%4< *35 O4-3-( !6) D-635()5 ",3,*;0=, (.650:4 (; D 9,*,7;69: P6;,5;0(3 -69 04796=,+ ;63,9()030;@ O.'/).' $/,,"#/1"3)/. 6)3( N"3)/.", I.23)343& /. D14' A#42& (NIDA) M '@?4=:?:42= 6G:56?46 @7 :>AC@G65 E@=6C23:=:EJ H:E9 -+/734 >2.5M 7,673, 05 $.". :<--,9 -964 67060+ <:, +0:69+,91
Slide 30: TRV045: Next-Generation S1P Modulator for CNS Disorders
TRV045: Ne'$-Gene"a$ion 51P Mod%la$o" fo" CN5 Di#o"de"# N,> MOA (; "1P, >0;/6<; (::6*0(;,+ 3@47/67,50( *:*67*7 P&.3 *75437* 100 ** * 80 M ,1) C646AE@CD :? E96 C', A=2J F?:BF6 C@=6 :? >@5F=2E:?8 ?6FC@EC2?D>:DD:@? / >6>3C2?6 6I4:E23:=:EJ 60 40 d yperalgesia 20 M #? 2?:>2=D, -+/045 C6G6CD65 A24=:E2I6=-
Slide 31: Trevena: Innovative CNS Company
5)9)2%: I2239%7-9) CNS C314%2< OLINVYK !) !$d!ca*ed !$ ad+"*) f%( * e #a$age#e$* %f ac+*e &a!$ )e,e(e e$%+g *% (e'+!(e a$ !$*(a,e$%+) %&!%!d a$a"ge)!c a$d f%( - %# a"*e($a*!,e *(ea*#e$*) a(e !$ade'+a*e. P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+""
Slide 32: Appendix
APPENDIX 32
Slide 33: Clinical Development Program
R3&867 C0-2-'%0 D)9)0341)27 P53+5%1 OLINVYK *+, #! #& > 1,900 #& #-# ,a$* Phase 1 Phase 2 Phase 3 M N4 )47&,* &)/9782*387 7@C 6=56C=J / C6?2==J :>A2:C65 '@ <?@H? 24E:G6 >6E23@=:E6D 4 -*&)-84--*&) 86.&17 :7. I$ 2465-.3*: M M M M #/ @A:@:5 677:424J +2A:5 @?D6E @7 24E:@? 06==-492C24E6C:K65 C6DA:C2E@CJ
Slide 34: Primary Efficacy Endpoint in Phase 3 Study
P5-1%5< E**-'%'< E2(43-27 A',-)9)( -2 :3 P-937%0 S78(-)6 OLIN%'K (*/0,=,+ I% 67060+ ,--0*(*@ # < 0.0001 p == 0.0004 80% p < 0.0001 70% 80% 70% p == 0.029 60% 60% 50% 50% 40% 40% 30% 30% 20% 10% 20% 10% 0% 0% #8-/1.; 0. 1 93 0. 35 93 0. 5 93 #8-/1.; 0. 1 93 0. 35 93 0. 5 93 -*)#%/)$),% -*)#%/)$),% P"
Slide 35: OLINVYK: Efficacy in Phase 3 Study
OLIN"$K: I" O4-3-( E**-'%'< -2 2 P,%6) 3 RC 6 $<=,A 1 (!:<078-,1+ D H):, %1;;=-) 3 $CA 9.025.6: :;<-2.-(0.1, 0.35, 0.5 50) =:. 84*,.+7 *44 -7:.: $<0.01 =:. 84*,.+7 10 9 8 7 6 5 4 3 2 1 0 P/%')&2 (1=? ) 0LIN#$K 0 10+ (1=?6) 0LIN#$K 0 350+ (1=? ) 0LIN#$K 0 50+ (1=? ) 0 4 8 12 16 20 24 28 32 36 40 44 4
Slide 36: No Accumulation Observed Dosing Limit
N3 A''8180%7-32 D)64-7) R)4)%7)( D36-2+ M<3;0-D6:, ; # ";<+@ K*= 6*79187 x 2 %( 3#g e,e(. 2 () 40093 (<;?5@5B1 A ": -//?8?7->5:9 >4<:?34 24 4<= !.*6 %(,I <105: *; 22 7/ 24 8726;: A ": /->13:<5/-7 %(/ :?>751<= C >60 5: >500 5: *+:74<;. A *177 >:71<->10, 9: 'AE=* 92% 9.*,1.-5*? -*24@ -7:. *",) )**)'6
Slide 37: Interaction Between the AT1 Receptor and ACE2 in COVID-19
ln$e"ac$i n Be$&een $he AT1 Rece!$ " and ACE2 in COVlD-19 D6>59,.<3(;065 6-ACE2 )@ *6965(=09<: 05+09,*;3@ 79646;,: (*;0=(;065 6-;/, A#1 9,*,7;69 C C6965(=09<: )05+: ;6 (5+ +6>59,.<3(;,: (5.06;,5:05 *65=,9;05. ,5A@4, 2 (ACE2)1 C D,*9,(:, 05 ACE2 ,3,=(;,: (5.06;,5:05 II 3,=,3: - A6/17;-6:16 II )+;1=);
Slide 38: Delta Receptor Agonists Have Unique Benefits
Del$a Rece $o" Agoni#$# Ha&e Uni!%e Benefi$# P6;,5;0(3 <;030;@ -69 ( =(90,;@ 6-CN" 05+0*(;065: T)#(+a&* I D#+a&* C #(9.,;: :,96;6505 9,*,7;69: 4,+0(;, =(:*<3(9 ,?*0;()030;@ ((::6*0(;,+ C% 90:2)1 C M0.9(05,-:7,*0-0* ;9,(;4,5; CGRP* C #(9.,;: CG!P 9,*,7;69: 9,.<3(;, 5,<965(3 :;9<*;<9,: 05=63=,+ 05 7(0
Slide 39: Important Safety Information
IMPORTANT SAFETY INFORMATION 3
Slide 40: Limitations of Use and Contraindications
L/2/9'9/438 4, "8+ B+)':8+ 4, 9.+ 7/808 4, '**/)9/43, '(:8+, '3* 2/8:8+ </9. 45/4/*8, +;+3 '9 7+)422+3*+* *48+8, 7+8+7;+ OLIN#$K ,47 :8+ /3 5'9/+398 ,47 <.42 '19+73'9/;+ 97+'92+39 459/438 %+.-., 343-45/4/* '3'1-+8/)8 47 45/4/* )42(/3'9/43 574*:)98&: G H';+ 349 (++3 941+7'9+*, 47 '7+ 349 +=5+)9+* 94
Slide 41: Warnings and Precautions
WARNINGS AND PRECAUTIONS • P74143-+* :8+ 4, 45/4/*8 *:7/3-57+-3'3)> )'3 7+8:19 /3 </9.*7'<'1 /3 9.+ 3+43'9+ 9.'9 2'> (+ 1/,+-9.7+'9+3/3-. O(8+7;+ 3+<(4738 ,47 8/-38 4, 3+43'9'1 45/4/* </9.*7'<'1 8>3*742+ '3* 2'3'-+ '))47*/3-1>. A*;/8+ 57+-3'39 <42+3 :8/3-OLIN#$K ,47 ' 574143-+* 5+7/4* 4, 9.+ 7/80 4,